Microlin Bio Inc. Licenses The Ohio State University’s miRNA Patent Portfolio to Advance Cancer Diagnostics & Therapeutics

September 26, 2013

COLUMBUS, Ohio, and NEW YORK, Sept. 26, 2013 /PRNewswire/ – The Ohio State University today announced the signing of an exclusive world-wide agreement with Microlin Bio Inc., licensing a large portfolio of Ohio State’s groundbreaking cancer discoveries. The portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat […]

Read the full article →

MicroRNA-31 Might Predict Lung-Cancer Spread

September 25, 2013

Determining whether lung cancer has spread is critical for identifying the most effective therapy. This study found that high levels of microRNA-31 indicate that the tumor has spread and signals a poor prognosis. The findings might lead to improved treatment for some people with the most common form of lung cancer. COLUMBUS, Ohio – Determining […]

Read the full article →

starBase v2.0: decoding miRNA-ncRNA, miRNA-ceRNA and protein-RNA interaction maps from large-scale CLIP-Seq data

September 23, 2013

starBase v2.0 update available starBase is a database that can be used for decoding miRNA-mRNA, miRNA-ceRNA, miRNA-lncRNA, miRNA-circRNA, miRNA-pseudogene and protein-RNA interaction networks from CLIP-Seq (HITS-CLIP, PAR-CLIP, iCLIP, CLASH) data. starBase v2.0 now also provides visualization, analysis, discovery and downloading of above-mentioned large-scale functional genomics data. Currently, starBase v.20 includes (1)108 CLIP-Seq datasets, (2)~500,000 miRNA-mRNA […]

Read the full article →

Exosome Blood-Based Biomarker Discovery: Eli Lilly Enters Collaboration Agreement with Exosome Diagnostics

September 19, 2013

NEW YORK, Sept. 19, 2013 /PRNewswire/ – Exosome Diagnostics today announced it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) for biomarker discovery and validation using Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit.  Under the agreement, Lilly will gain early access to Exosome Diagnostics technology to help identify key gene mutations and […]

Read the full article →

EpimiRNA Consortium Receives €11.5 Million Funding by EU to Uncover the Effects of microRNA in Epilepsy

September 18, 2013

September 18, 2013 / B3C newswire / - Major new funding for research into epilepsy is announced today. The EpimiRNA Consortium, involving 16 partners from 8 European countries, the USA and Brazil has received €11.5 million funding from the European Union’s Framework Programme 7 to investigate molecular mechanisms, diagnostics and treatments for epilepsy. Over 50 million people […]

Read the full article →

Rosetta Genomics Reports Financial Results for the First Six Months of 2013

September 10, 2013

Demonstrating Increased Demand for the Rosetta Cancer Origin Test PRINCETON, NJ and REHOVOT, ISRAEL–(Marketwired – Sep 10, 2013) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reports financial results for the six months ended June 30, 2013. Commercial highlights for the first half of 2013 and recent weeks include: Enhanced […]

Read the full article →

Frost & Sullivan: Diagnostic and Therapeutic Potential of microRNAs Stimulate Need for More Research Tools

September 4, 2013

Product innovation and the development of high-qualitative assays are the need of the hour LONDON, Sept. 4, 2013 /PRNewswire/ — Rapid growth in microRNA (miRNA) research over the past two years, owing to its diagnostic and therapeutic potential, has fueled development in the global miRNA tools and services market. Of the various miRNA technologies, which include quantitative […]

Read the full article →

Call for Speakers – microRNA as Biomarkers and Diagnostics

August 27, 2013

Cambridge Healthtech Institute is currently accepting speaking proposals for the 10th Annual microRNA as Biomarkers and Diagnostics Conference to take place March 17-18, 2014 in Boston. The meeting will cover the latest developments in the use of microRNA in the early detection of disease for more effective treatment, monitoring tumor growth and disease progression, issues […]

Read the full article →

Serum miR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer

June 19, 2013

Highly sensitive and accurate test detects cancer-related microRNA in blood of patients even before the development of colorectal cancer DALLAS, June 19, 2013 /PRNewswire-USNewswire/ – A new blood test developed in the Gastrointestinal Cancer Research Lab at Baylor Research Institute is showing very promising results for finding cancer-related microRNA in the blood before a tumor develops […]

Read the full article →

Release of miRBase 20 approaching

June 17, 2013

It has been almost a year since the last miRBase update and according to Sam from miRBase we should see the release of miRBase 20  within this week: “As you might expect, the extended period since the last release means many new entries — over 3000 new stem-loop sequences, and over 5000 new mature sequences. […]

Read the full article →